^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation
Excerpt:
...An exon 21 L858R mutation has been found in high-sensitivity EGFR mutation tests by PCR using tumor tissue centrally confirmed....
Trial ID:
Source:
Title:
Effect of bevacizumab plus double dose icotinib on advanced non-small cell lung cancer with EGFR L858R mutation.
Published date:
05/25/2023
Excerpt:
In this study, we would investigate the efficacy of the combined therapy bevacizumab and double-dose icotinib for advanced NSCLC patients with EGFR L858R mutation….For 30 patients with complete efficacy evaluation data, 20 patients achieved partial responses (PR), 9 patients had stable disease (SD), and 1 patient developed progress disease (PD). The objective response rate (ORR) was 66.7%, the disease control rate (DCR) was 96.7%, and the median PFS was 14.8 months.....The combination of bevacizumab with double-dose icotinib is an effective and relatively safe treatment for advanced NSCLC patients with EGFR L858R mutation.
DOI:
10.1200/JCO.2023.41.16_suppl.e21020
Trial ID:
Source:
Title:
Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study
Published date:
07/13/2021
Excerpt:
...a prolonged median PFS was observed in the cases harboring exon 21 point mutation (Ex21.L858R) in the IB group compared to the I group... first study to provide further evidence of the benefits of applying icotinib in combination with bevacizumab as first-line treatment for advanced NSCLC cases harboring EGFR mutations.
DOI:
https://doi.org/10.1111/1759-7714.14079
